253 related articles for article (PubMed ID: 18483302)
41. Reversine exhibits antineoplastic activity in JAK2
Lima K; Carlos JAEG; Alves-Paiva RM; Vicari HP; Souza Santos FP; Hamerschlak N; Costa-Lotufo LV; Traina F; Machado-Neto JA
Sci Rep; 2019 Jul; 9(1):9895. PubMed ID: 31289316
[TBL] [Abstract][Full Text] [Related]
42. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.
Warner SL; Bashyam S; Vankayalapati H; Bearss DJ; Han H; Mahadevan D; Von Hoff DD; Hurley LH
Mol Cancer Ther; 2006 Jul; 5(7):1764-73. PubMed ID: 16891462
[TBL] [Abstract][Full Text] [Related]
43. Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases.
Bavetsias V; Sun C; Bouloc N; Reynisson J; Workman P; Linardopoulos S; McDonald E
Bioorg Med Chem Lett; 2007 Dec; 17(23):6567-71. PubMed ID: 17933533
[TBL] [Abstract][Full Text] [Related]
44. Reversine inhibits spontaneous synaptic transmission in cultured rat hippocampal neurons.
Li R; Zhu S; He X; Xie Z
Cell Biol Int; 2007 Jun; 31(6):540-5. PubMed ID: 17258475
[TBL] [Abstract][Full Text] [Related]
45. Autophagy induction of reversine on human follicular thyroid cancer cells.
Lu CH; Liu YW; Hua SC; Yu HI; Chang YP; Lee YR
Biomed Pharmacother; 2012 Dec; 66(8):642-7. PubMed ID: 23089471
[TBL] [Abstract][Full Text] [Related]
46. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
[TBL] [Abstract][Full Text] [Related]
47. Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents.
Sharma S; Zeng JY; Zhuang CM; Zhou YQ; Yao HP; Hu X; Zhang R; Wang MH
Mol Cancer Ther; 2013 May; 12(5):725-36. PubMed ID: 23468529
[TBL] [Abstract][Full Text] [Related]
48. S39, a novel Aurora B kinase inhibitor, shows potent antineoplastic activity in human Hela cervical cancer cell line.
Li J; Lang Q; Zhang H; Huang Q; Yu L
Biotechnol Lett; 2013 Jun; 35(6):853-60. PubMed ID: 23443212
[TBL] [Abstract][Full Text] [Related]
49. Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3R
Parducci NS; Garnique ADMB; Lima K; Carlos JAEG; Fonseca NP; de Miranda LBL; de Almeida BO; Rego EM; Traina F; Machado-Neto JA
Blood Cells Mol Dis; 2024 Jan; 104():102799. PubMed ID: 37839173
[TBL] [Abstract][Full Text] [Related]
50. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
51. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
[TBL] [Abstract][Full Text] [Related]
52. p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells.
Ikezoe T; Yang J; Nishioka C; Yokoyama A
Int J Hematol; 2010 Jan; 91(1):69-77. PubMed ID: 20013323
[TBL] [Abstract][Full Text] [Related]
53. Reversine induces cell cycle arrest and apoptosis via upregulation of the Fas and DR5 signaling pathways in human colorectal cancer cells.
Park YL; Ha SY; Park SY; Choi JH; Jung MW; Myung DS; Kim HS; Joo YE
Int J Oncol; 2019 May; 54(5):1875-1883. PubMed ID: 30864676
[TBL] [Abstract][Full Text] [Related]
54. Investigating the role of Aurora kinases in RAS signaling.
Kosik A; Bekier ME; Katusin JD; Kaur H; Zhou X; Diakonova M; Chadee DN; Taylor WR
J Cell Biochem; 2009 Jan; 106(1):33-41. PubMed ID: 19009561
[TBL] [Abstract][Full Text] [Related]
55. Tetraploidization increases sensitivity to Aurora B kinase inhibition.
Marxer M; Foucar CE; Man WY; Chen Y; Ma HT; Poon RY
Cell Cycle; 2012 Jul; 11(13):2567-77. PubMed ID: 22722494
[TBL] [Abstract][Full Text] [Related]
56. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
[TBL] [Abstract][Full Text] [Related]
57. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.
Hartsink-Segers SA; Zwaan CM; Exalto C; Luijendijk MW; Calvert VS; Petricoin EF; Evans WE; Reinhardt D; de Haas V; Hedtjärn M; Hansen BR; Koch T; Caron HN; Pieters R; Den Boer ML
Leukemia; 2013 Mar; 27(3):560-8. PubMed ID: 22940834
[TBL] [Abstract][Full Text] [Related]
58. The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms.
Jetton N; Rothberg KG; Hubbard JG; Wise J; Li Y; Ball HL; Ruben L
Mol Microbiol; 2009 Apr; 72(2):442-58. PubMed ID: 19320832
[TBL] [Abstract][Full Text] [Related]
59. The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.
Nair JS; Ho AL; Schwartz GK
Cell Cycle; 2012 Feb; 11(4):807-17. PubMed ID: 22293494
[TBL] [Abstract][Full Text] [Related]
60. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
Schöffski P; Jones SF; Dumez H; Infante JR; Van Mieghem E; Fowst C; Gerletti P; Xu H; Jakubczak JL; English PA; Pierce KJ; Burris HA
Eur J Cancer; 2011 Oct; 47(15):2256-64. PubMed ID: 21852114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
